Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherClinical Investigations (Human)

Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions

Maurits Wondergem, Friso M van der Zant, Wouter AM Broos and Remco JJ Knol
Journal of Nuclear Medicine February 2021, jnumed.120.258574; DOI: https://doi.org/10.2967/jnumed.120.258574
Maurits Wondergem
Noordwest Ziekenhuisgroep, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Friso M van der Zant
Noordwest Ziekenhuisgroep, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wouter AM Broos
Noordwest Ziekenhuisgroep, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Remco JJ Knol
Noordwest Ziekenhuisgroep, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction: Tens of different PSMA targeting radiopharmaceuticals for both imaging and therapy have been synthesized. Although variability in biodistribution and affinity for binding to the PSMA receptor between different PSMA targeting radiopharmaceuticals are known, little is known about the clinical implications of those variabilities. Therefore in this study differences in inter-reader agreement and detection rate between two regularly used 18F-labeled PSMA-receptor targeting radiopharmaceuticals [18F]-DCFPyL and [18F]-PSMA-1007 were analyzed. Material and Methods: One hundred and twenty consecutive patients scanned with [18F]-PSMA-1007 were match-paired with 120 patients scanned with [18F]-DCFPyL. All 240 PET/CTs were reviewed by two readers and scored according to PSMA-RADS reading criteria for PSMA PET/CT. Inter-reader agreement and detection rate of suspected lesions were scored for different anatomical locations including prostate/prostatic fossa, lymph nodes, bone, and other locations. Results: Large equality between [18F]-DCFPyL and [18F]-PSMA-1007 was found; however, some clinically relevant and statistically significant differences were observed. [18F]-PSMA-1007 detected suspected prostatic/prostatic fossa lesions in a higher proportion of patients and especially in the subcohort of patients scanned for biochemical recurrence. [18F]-DCFPyL and [18F]-PSMA-1007 showed equal ability for detection of suspected lymph nodes, although inter-reader agreement for [18F]-DCFPyL was higher. [18F]-DCFPyL showed less equivocal skeletal lesions and higher inter-reader agreement for skeletal lesions. Conclusion: Clinical relevant differences, which may account for diagnostic dilemmas, were observed between of [18F]-DCFPyL and [18F]-PSMA-1007. Those findings encourage further studies, as they may have consequences for selection of the proper PSMA targeting radiopharmaceutical.

  • Genitourinary
  • Oncology: GU
  • PET/CT
  • PET/CT
  • PSMA
  • Prostate cancer
  • [18F]-DCFPyL
  • [18F]-PSMA-1007
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions
Maurits Wondergem, Friso M van der Zant, Wouter AM Broos, Remco JJ Knol
Journal of Nuclear Medicine Feb 2021, jnumed.120.258574; DOI: 10.2967/jnumed.120.258574

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Matched-pair comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 prostate cancer patients; inter-reader agreement and lesion detection rate of suspected lesions
Maurits Wondergem, Friso M van der Zant, Wouter AM Broos, Remco JJ Knol
Journal of Nuclear Medicine Feb 2021, jnumed.120.258574; DOI: 10.2967/jnumed.120.258574
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • 18F-FDG PET/MRI for staging and interim response assessment in pediatric and adolescent Hodgkin lymphoma: a prospective study with 18F-FDG PET/CT as reference standard
  • Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
  • A Prospective Randomized, Double-blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-differentiated Neuroendocrine Tumors
Show more Clinical Investigations (Human)

Clinical (Oncology: GU)

  • Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen (PSMA)-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
  • Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET/CT – effects on lesion visibility and radiotracer uptake
  • Diagnostic Value, Oncological Outcomes And Safety Profile Of Image-Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy For Prostate Cancer.
Show more Clinical (Oncology: GU)

Similar Articles

Keywords

  • Genitourinary
  • Oncology: GU
  • PET/CT
  • PSMA
  • prostate cancer
  • [18F]-DCFPyL
  • [18F]-PSMA-1007
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire